ArticleMedicine2025
Blood metabolites and gastric cancer risk: A bidirectional 2-sample Mendelian randomization study.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Assessing the impact of metabolomic markers on gastric cancer risk: a two-sample Mendelian randomization study.Korean journal of family medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Notably, metabolic dysregulation stands as a prominent characteristic of cancer. The identification of biomarkers through blood metabolomics presents a novel approach for the diagnosis and treatment of gastric cancer. We performed a 2-sample Mendelian randomization (MR) analysis to assess the causality from genetically proxied 486 blood metabolites to gastric cancer. In this study, MR analysis was employed to assess the correlation between 486 serum metabolites and gastric cancer. Five different methods, namely inverse-variance weighting, MR-Egger method, weighted median method, simple mode method, and weighted mode method, were utilized for evaluation. Sensitivity analysis was conducted, encompassing heterogeneity testing, horizontal pleiotropy testing, and leave-one-out testing. Furthermore, the study encompassed linkage disequilibrium score (LDSC) genetic association and directionality assessment, metabolic pathway analysis, and reverse MR analysis. The findings revealed the presence of 21 metabolites, comprising 14 known metabolites and 7 unidentified metabolites that potentially play a causal role in gastric cancer. The reverse MR and directional assessment indicated the absence of reverse causality between gastric cancer and the candidate metabolites. Moreover, the LDSC genetic association solely identified a genetic association between gastric cancer and the unknown metabolite X-11315. Additionally, the metabolic pathway analysis identified 3 pathways that may be implicated in the development of the disease. We observed negative correlations between 12 serum metabolites and the risk of gastric cancer, while 9 serum metabolites showed positive correlations. Notably, 3-methyl-2-oxovalerate exhibited promising therapeutic potential, whereas 2-aminobutyrate displayed a higher risk factor. The integration of genomics and metabolomics in our investigation offers novel insights into the underlying mechanisms of gastric cancer, thereby holding significant implications for the screening and prevention of this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.